iCardioTox Profiler - Developing a Novel In Vitro Assay to Assess Cardiotoxicity Using a Panel of Patient-derived Cardiomyocytes

Period of Performance: 02/01/2017 - 07/31/2017

$150K

Phase 1 SBIR

Recipient Firm

Stem Cell Theranostics, Inc.
REDWOOD CITY, CA 94063
Principal Investigator

Abstract

Abstract This proposed NIH SBIR Phase I Project by Stem Cell Theranostics (SCT) is aimed at developing a novel in vitro pre-clinical screening platform to predict drug-induced cardiotoxicity. Cardiotoxicity is the most serious adverse drug reaction in clinical development and a leading cause of late stage drug failures. The pharmaceutical industry is under growing pressure to correct declining productivity, which is increasingly driven by the high level of late stage drug failures. It is now estimated that the average cost to bring a new drug to market is more than $2.6 billion dollars. To reduce high attrition rates and increased costs, drug developers need to be able to identify potential safety issues as early as possible during the drug discovery process. Doing so would enable more attention to be focused on programs with optimal chances of progressing through end- stage clinical trials rather than on costly failures. The overall focus of this proposal is to develop a screening assay, using a panel of patient-derived cardiomyocytes and standardized methods, to rapidly assess cardiotoxicity. Our patient- and disease-specific human induced pluripotent stem cell-derived cardiomyocytes (iPSC-CM) models address an urgent need: a means for investigators to perform in vitro toxicity testing of their compounds on human cells before in vivo testing. These preclinical models: (1) enable faster critical decisions by prioritizing drug candidates, and (2) dramatically reduce development costs by predicting clinical outcomes. Using patient-derived iPSC-CMs as translational models holds the promise of revolutionizing drug discovery and development. The streamlined drug toxicity testing made possible by this innovation has the potential to bridge the ?Valley of Death? created by phenomenal drug attrition and catalyze a shift to a new drug development paradigm where life-threatening hazards to human health are predicted early in development. Successful completion of this project will lead to improved detection of cardiotoxicity early in the drug discovery process. Importantly, this project will pave the path for using cardiac disease models to improve toxicity testing and will set precedence for using precision methods and disease models to inform drug discovery. Our goal is to enable the development of safer drugs and dramatically reduce development costs.